Work

Is active surveillance a good treatment option for stage 1 seminoma in a developing nation? Long-term outcomes from the Indian subcontinent

Year: 2025

Type: article

Abstract: Background: Stage 1 seminoma is treated with high inguinal orchiectomy (HIO) followed by either chemotherapy, radiation therapy (RT) or active surveillance (AS).Methods: This was a retrospective analysis of a prospectively collected dataset of patients with seminoma treated at a comprehensive cancer care centre in India.Adolescent and adult males with stage 1 seminoma were included.Results: A total of 114 patients were analysed.The median age was 39 years (IQR: 32-48 years).Stage IA was more frequently seen and 105 (92.1%) patients underwent unilateral HIO.Chemotherapy was offered to 66 (57.9%) patients.AS was offered to 32 (28.1%) patients while RT was offered to 16 (14%).Only 14 (43.8%) of the 32 patients on AS strictly adhered to the institutional follow-up guidelines for at least 2 years post treatment.Of the 114 patients, 9 (7.9%) patients had radiological relapse, while 4 (3.5%) of them were symptomatic at relapse.Bleomycin, etoposide and cisplatin were the most common regimen offered on relapse.The median follow-up of the cohort was 70.6 months (95% CI: 59.1-82 months).The mean relapse-free survival (RFS) was 107.7 months (95% CI: 102.5-112.8months).The 1-, 2-and 5-year RFS were 97.3%, 95.5% and 92.4%, respectively.The mean overall survival (OS) was 114.9 months (95% CI: 113.2-116.6 months).The 2-, 5-and 8-year OS were 100%, 98.9% and 98.9%, respectively.There was no statistically significant benefit of 2 cycles over 1 cycle of carboplatin in terms of median RFS (96.5 versus 108.8 months, p = 0.260) or 5-year OS (95% versus 100%, p = 0.192).There was no statistically significant difference in RFS (p = 0.355) or OS (p = 0.684) based on treatment offered at baseline.There was no difference in survival between patients who strictly adhered to follow-up guidelines versus those who did not.

Source: ecancermedicalscience

DOI: 10.3332/ecancer.2025.1994